Compare FONR & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FONR | SERA |
|---|---|---|
| Founded | 1978 | 2008 |
| Country | United States | United States |
| Employees | N/A | 64 |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.9M | 134.3M |
| IPO Year | 1987 | 2021 |
| Metric | FONR | SERA |
|---|---|---|
| Price | $18.69 | $3.56 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 149.7K | 66.5K |
| Earning Date | 02-17-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.08 | N/A |
| Revenue | ★ $105,434,318.00 | $95,000.00 |
| Revenue This Year | N/A | $25.84 |
| Revenue Next Year | N/A | $715.79 |
| P/E Ratio | $17.27 | ★ N/A |
| Revenue Growth | ★ 3.36 | 1.06 |
| 52 Week Low | $12.00 | $1.37 |
| 52 Week High | $18.86 | $6.92 |
| Indicator | FONR | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 80.23 | 55.57 |
| Support Level | $18.50 | $3.30 |
| Resistance Level | $18.67 | $3.85 |
| Average True Range (ATR) | 0.06 | 0.25 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 74.51 | 72.38 |
Fonar Corp is a United States-based company which is engaged in the business of designing, manufacturing, selling and servicing magnetic resonance imaging (MRI) scanners, which utilize MRI technology for the detection and diagnosis of human disease, abnormalities, other medical conditions, and injuries. The company operates through two segments namely Manufacturing and servicing of medical equipment; and the Management of diagnostic imaging centers, which generates a vast majority of the revenue.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.